FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018556051> ?p ?o ?g. }

• W2018556051 endingPage "1148" @default.
• W2018556051 startingPage "1136" @default.
• W2018556051 abstract "The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us (J. Med. Chem. 2011. 54, 8563). In the current study, based on the prior results, we have developed structure–activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines." @default.
• W2018556051 created "2016-06-24" @default.
• W2018556051 creator A5008699306 @default.
• W2018556051 creator A5012245576 @default.
• W2018556051 creator A5016346851 @default.
• W2018556051 creator A5020529282 @default.
• W2018556051 creator A5034843478 @default.
• W2018556051 creator A5042495906 @default.
• W2018556051 creator A5048639910 @default.
• W2018556051 creator A5055762119 @default.
• W2018556051 creator A5061403166 @default.
• W2018556051 creator A5063067549 @default.
• W2018556051 creator A5063566841 @default.
• W2018556051 creator A5064411392 @default.
• W2018556051 creator A5070580886 @default.
• W2018556051 creator A5090325831 @default.
• W2018556051 date "2013-01-18" @default.
• W2018556051 modified "2023-09-23" @default.
• W2018556051 title "Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1<i>H</i>-benzimidazole Derivatives" @default.
• W2018556051 cites W1493920337 @default.
• W2018556051 cites W1965344095 @default.
• W2018556051 cites W1966114716 @default.
• W2018556051 cites W1976003215 @default.
• W2018556051 cites W1981652396 @default.
• W2018556051 cites W1985588649 @default.
• W2018556051 cites W2017148342 @default.
• W2018556051 cites W2027482274 @default.
• W2018556051 cites W2029428708 @default.
• W2018556051 cites W2038840577 @default.
• W2018556051 cites W2051410494 @default.
• W2018556051 cites W2055904567 @default.
• W2018556051 cites W2059097089 @default.
• W2018556051 cites W2081210324 @default.
• W2018556051 cites W2084637523 @default.
• W2018556051 cites W2095722179 @default.
• W2018556051 cites W2096454260 @default.
• W2018556051 cites W2118906905 @default.
• W2018556051 cites W2119504728 @default.
• W2018556051 cites W2122680090 @default.
• W2018556051 cites W2124026197 @default.
• W2018556051 cites W2127226545 @default.
• W2018556051 cites W2151702398 @default.
• W2018556051 cites W2157592394 @default.
• W2018556051 cites W2163144362 @default.
• W2018556051 cites W2163341755 @default.
• W2018556051 cites W2167398093 @default.
• W2018556051 cites W2168249158 @default.
• W2018556051 cites W2180229411 @default.
• W2018556051 cites W2319371745 @default.
• W2018556051 cites W25487609 @default.
• W2018556051 doi "https://doi.org/10.1021/jm3015712" @default.
• W2018556051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23301637" @default.
• W2018556051 hasPublicationYear "2013" @default.
• W2018556051 type Work @default.
• W2018556051 sameAs 2018556051 @default.
• W2018556051 citedByCount "77" @default.
• W2018556051 countsByYear W20185560512013 @default.
• W2018556051 countsByYear W20185560512014 @default.
• W2018556051 countsByYear W20185560512015 @default.
• W2018556051 countsByYear W20185560512016 @default.
• W2018556051 countsByYear W20185560512017 @default.
• W2018556051 countsByYear W20185560512018 @default.
• W2018556051 countsByYear W20185560512019 @default.
• W2018556051 countsByYear W20185560512020 @default.
• W2018556051 countsByYear W20185560512021 @default.
• W2018556051 countsByYear W20185560512022 @default.
• W2018556051 countsByYear W20185560512023 @default.
• W2018556051 crossrefType "journal-article" @default.
• W2018556051 hasAuthorship W2018556051A5008699306 @default.
• W2018556051 hasAuthorship W2018556051A5012245576 @default.
• W2018556051 hasAuthorship W2018556051A5016346851 @default.
• W2018556051 hasAuthorship W2018556051A5020529282 @default.
• W2018556051 hasAuthorship W2018556051A5034843478 @default.
• W2018556051 hasAuthorship W2018556051A5042495906 @default.
• W2018556051 hasAuthorship W2018556051A5048639910 @default.
• W2018556051 hasAuthorship W2018556051A5055762119 @default.
• W2018556051 hasAuthorship W2018556051A5061403166 @default.
• W2018556051 hasAuthorship W2018556051A5063067549 @default.
• W2018556051 hasAuthorship W2018556051A5063566841 @default.
• W2018556051 hasAuthorship W2018556051A5064411392 @default.
• W2018556051 hasAuthorship W2018556051A5070580886 @default.
• W2018556051 hasAuthorship W2018556051A5090325831 @default.
• W2018556051 hasConcept C121608353 @default.
• W2018556051 hasConcept C126322002 @default.
• W2018556051 hasConcept C178790620 @default.
• W2018556051 hasConcept C185592680 @default.
• W2018556051 hasConcept C2776551883 @default.
• W2018556051 hasConcept C2777911890 @default.
• W2018556051 hasConcept C2778313021 @default.
• W2018556051 hasConcept C2778484023 @default.
• W2018556051 hasConcept C2779322244 @default.
• W2018556051 hasConcept C2779723316 @default.
• W2018556051 hasConcept C2780192828 @default.
• W2018556051 hasConcept C2780962315 @default.
• W2018556051 hasConcept C2781253882 @default.
• W2018556051 hasConcept C2910016293 @default.
• W2018556051 hasConcept C2910322876 @default.
• W2018556051 hasConcept C502942594 @default.

• next